Cargando…

The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities

Despite the promising clinical benefits of therapies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) with antibodies in various cancers, resistance to these therapies will inevitably develop following treatment. Recent studies suggest that crosstalk bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Lan, Wang, Lihua, Zhang, Jinzhao, Zhao, Le, Meng, Yun, Zheng, Jidai, Xu, Wei, Zhu, Zhenping, Huang, Haomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360952/ https://www.ncbi.nlm.nih.gov/pubmed/37484224 http://dx.doi.org/10.1016/j.heliyon.2023.e16922

Ejemplares similares

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
por: Li, Li, et al.
Publicado: (2020)

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
por: Kim, Da-Hyun, et al.
Publicado: (2020)

A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
por: Zhao, Jie, et al.
Publicado: (2022)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
por: Castoldi, R, et al.
Publicado: (2013)

A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
por: Ma, Mingshu, et al.
Publicado: (2012)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β
por: Sehlin, Dag, et al.
Publicado: (2017)

An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer
por: Guo, Xiao-Fang, et al.
Publicado: (2014)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle
por: Li, Yongqi, et al.
Publicado: (2023)

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells
por: Soto-Gamez, Abel, et al.
Publicado: (2020)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model
por: Gupta, Vijay R., et al.
Publicado: (2020)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
por: Pan, Haitao, et al.
Publicado: (2018)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

Erythrocyte-mimicking paclitaxel nanoparticles for improving biodistributions of hydrophobic drugs to enhance antitumor efficacy
por: Zhai, Zheng, et al.
Publicado: (2020)

Optimization on biodistribution and antitumor activity of tripterine using polymeric nanoparticles through RES saturation
por: Yin, Juntao, et al.
Publicado: (2017)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
por: Iosifidou, R, et al.
Publicado: (2009)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Fusion exhibition
Publicado: (1993)

Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow
por: Boswell, C. Andrew, et al.
Publicado: (2011)

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)

Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome
por: Wang, Hongbo, et al.
Publicado: (2014)

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
por: Liu, Yingqiang, et al.
Publicado: (2021)

A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action
por: Mohan, Nishant, et al.
Publicado: (2021)

Epigallocatechin Gallate-Gold Nanoparticles Exhibit Superior Antitumor Activity Compared to Conventional Gold Nanoparticles: Potential Synergistic Interactions
por: Chavva, Suhash Reddy, et al.
Publicado: (2019)

Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies
por: Silva Lima, Beatriz, et al.
Publicado: (2018)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
por: Rubio-Pérez, Laura, et al.
Publicado: (2023)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ntf6eptamsfdass3h65ambsp48